Chen Li-kun, Xu Guang-chuan, Teng Xiao-yu, Liang Ying, Liu Jun-ling, Zhou Xian-mei
Department of Medical Oncology, Cancer Center, Sun Yat-sen University, Guangzhou 510060, P. R. China.
Ai Zheng. 2002 Aug;21(8):903-6.
BACKGROUND & OBJECTIVE: Adriamycin, dacarbazine and ifosfamide are three effective chemotherapy drugs in treating progressive soft tissue sarcoma. However, few regimen is effective for the patients who failed in treatment with prior Adriamycin and ifosfamide at standard dose. This study was designed to observe and evaluate the efficacy and toxicity of high dose ifosfamide(HDI) regimen on pre-treated soft tissue sarcoma.
Ten patients with advanced soft tissue sarcoma and 5 patients after surgical resection were treated with HDI administered by continuous infusion at a dose of 14 g/m2 per cycle over 6 days. All patients were pretreated with anthracycline +/- standard dose ifosfamide.
An overall response rate of 40% was observed with 2 complete and 2 partial remission. In the follow up at 4-48 month, the overall median survival time was 21 +/- 3.29 months and the median response duration was 6 +/- 1.45 months. The major toxicity was myelosuppression. 45.9% patients experienced grade 3-4 neutropenia.
HDI is an active salvage regimen in anthracycline +/- standard dose ifosfamide pretreated soft tissue sarcoma.
阿霉素、达卡巴嗪和异环磷酰胺是治疗进展性软组织肉瘤的三种有效化疗药物。然而，对于先前接受标准剂量阿霉素和异环磷酰胺治疗失败的患者，很少有方案有效。本研究旨在观察和评估高剂量异环磷酰胺（HDI）方案对预处理软组织肉瘤的疗效和毒性。
10例晚期软组织肉瘤患者和5例手术切除后的患者接受HDI治疗，以14 g/m²的剂量连续输注6天，每周期一次。所有患者均接受过蒽环类药物和/或标准剂量异环磷酰胺预处理。
观察到总缓解率为40%，其中2例完全缓解，2例部分缓解。在4-48个月的随访中，总中位生存时间为21±3.29个月，中位缓解持续时间为6±1.45个月。主要毒性为骨髓抑制。45.9%的患者出现3-4级中性粒细胞减少。
HDI是蒽环类药物和/或标准剂量异环磷酰胺预处理的软组织肉瘤的一种有效的挽救方案。
